DALLAS, TX - 07/11/2017 (PRESS RELEASE JET) — CTL Medical Corporation, a Dallas-based medical device manufacturing and service company, announced today that it has reached a national partnership agreement with G-21, an Italian-based biomaterials company. As a result, CTL Medical will now co-market G-21’s Bone Cement, Kyphoplasty and Vertebroplasty technologies in the United States.
“With the G-21 partnership, CTL Medical continues to fulfill its mission of becoming a fully integrated medical device design, development and manufacturing company serving the practice of spine surgery,” said Daniel Chon, president and CEO. “We intend to begin immediate distribution of the full line of acrylic-based bone cements for widespread procedures necessary for vertebrae consolidation and stabilization.”
The partnership becomes an innovative addition to CTL Medical’s existing spine and orthopedics portfolio, offering limitless application possibilities. The initial implementation of the distribution will include providing the FDA-approved bone cement and accompanying kit for the broadly adopted procedure of Kyphoplasty. This procedure involves the surgical filling of an injured or collapsed vertebra to relieve pain caused by spinal compression.
Each of the cement kits comes in the form of a two-component system composed of a liquid and powder, to be mixed at the time of application in the surgical suite. Various mixtures of the cement compounds are flexible in their working time and viscosity, based on the specific need of individual health care providers. The G-21 bone cement kits offer health care providers the maximum level of safety and control of mechanical properties during procedures, higher than typical reference standards.
For more information on CTL Medical Corporation, visit www.ctlmed.com.
About CTL Medical Corporation
CTL Medical Corporation was established in 2015 by Daniel Chon, with the vision of creating a fully integrated, industry leading, global medical device design, development and manufacturing company. CTL has assembled a world-class executive team, bringing together some of the industry’s most exceptional talent, further extending their position as a leader in medical device design and manufacturing. For more information, visit www.ctlmed.com.
G-21 was founded in 2009 by experienced entrepreneurs from the medical and pharmaceutical sector. G-21 has a portfolio of products including long-term implantable medical devices and Class III, designed as a result of extensive research and development programs conducted internally and in collaboration with leading research institutions and international universities. G-21 uses raw materials of high quality, executes absolute control of processes, ensures compliance with the most stringent international quality standards and conducts continuous staff training with extreme attention to detail. This includes clean room certification to the ISO Class-5 standards for the execution of processes in a completely sterile condition. For more information, visit www.G21Medical.com.
Media Contacts:Company Name: TrizCom PR